Rise Therapeutics

Focus: Rise Therapeutics is an early-stage biotech founded in 2022 focused on orally bioavailable protein therapeutics across immunotherapy and biologics. The company is pre-revenue with a nascent pipeline in Phase 1 development.

Biologics Immunotherapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Rise Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Rise Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

R-5780

Solid Tumor, Adult

Phase 1

Clinical Trials (1)

NCT06398418R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

Phase 1

Help build intelligence for Rise Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on innovative oral protein delivery technology—a differentiated modality with significant technical and commercial potential if successful
Ground-floor role at a 2022 founding with broad pipeline spanning oncology, immunology, and endocrinology, offering exposure across multiple therapeutic areas
Early-stage biotech environment enables direct impact on drug discovery, candidate selection, and translational strategy before later-stage bureaucracy sets in

Watch Out For

Extremely early stage (6 Phase 1 programs, no published data, founded 2022) means significant scientific and regulatory risk; no proof-of-concept validation in humans yet
Only 3 active job openings and no disclosed funding/employee count suggest limited near-term growth or organizational clarity; pre-revenue status creates cash burn uncertainty

Generated by Claude from Rise Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

R-5280

Type 1 Diabetes

Phase 1

Clinical Trials (1)

NCT06057454R-5280 in Newly Diagnosed Patients With Type 1 Diabetes

Phase 1

R-3750

COPD (Chronic Obstructive Pulmonary Disease)

Phase 1

Clinical Trials (1)

NCT07076290A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD

Phase 1